In a large cohort of 707 consecutive patients with symptomatic CAD, the association of platelet-derived PCSK9 and platelet aggregation was evaluated demonstrating that PCSK9 inhibition significantly reduced platelet-dependent thrombus formation (46). Here, PCSK9 is linked to coronary artery disorder.